What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?

Shares of a little-known biotechnology stock called Metsera (NASDAQ: MTSR) popped on Monday, Sept. 22, after Pfizer (NYSE: PFE) announced it would be acquiring it for a steep premium. Under the terms of the agreement, Pfizer will spend $47.50 per share, or about $4.9 billion up front.In addition to an up-front payment that is 43% above the previous trading day's closing price, Metsera shareholders will receive a contingent value rights (CVR) that could be worth up to $22.50 per share, if the anti-obesity candidates Pfizer acquired succeed.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool